Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

ld cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stage drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at http://www.lorusthera.com. For Lorus' regulatory filings on SEDAR, pl
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... Canada Endoscopy Visualization Systems Market Outlook ... Canada Endoscopy Visualization Systems market. The report provides ... units) and average prices (in US dollars) within ... Endoscopy Visualization Systems and Low-End Endoscopy Visualization Systems. ... , The report also provides company shares and ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... 2014 Amgen (NASDAQ: AMGN ) ... $0.61 per share dividend for the third quarter of ... 2014, to all stockholders of record as of the ... About Amgen Amgen is committed to unlocking the ... by discovering, developing, manufacturing and delivering innovative human therapeutics. ...
(Date:7/25/2014)... live in each person,s digestive tract. Scientists believe that ... off harmful infections, but their role in human health ... on the role of these bacteria, a team of ... tracked fluctuations in the bacterial populations of two research ... the July 25 issue of the journal Genome ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... Materials Research Laboratory at UC Santa Barbara: an NSF ... from the National Science Foundation (NSF) to carry out ... years. Renewed NSF support ensures the vitality of materials ... energy, environment, and sustainability. Despite the challenging budgetary ...
... Sept. 12, 2011 McKesson Corporation ... McKesson Specialty Health , focused on empowering the ... technology and quality of care. (Logo:   ... support and business solutions, McKesson Specialty Health offers the ...
... Sept. 9, 2011 Palatin Technologies, Inc. (NYSE Amex: ... the Rodman & Renshaw Annual Global Investment Conference on Tuesday, ... will be held at The Waldorf Astoria in New York, ... Executive Officer of Palatin Technologies, will provide an update on ...
Cached Biology Technology:Major grant from the National Science Foundation will sustain UCSB materials research through 2017 2Major grant from the National Science Foundation will sustain UCSB materials research through 2017 3McKesson Corporation Unveils New Offerings to Empower the Community Patient Care Delivery System 2McKesson Corporation Unveils New Offerings to Empower the Community Patient Care Delivery System 3
(Date:7/25/2014)... In the first broad-scale estimate of air pollution removal ... calculated that trees are saving more than 850 human ... respiratory symptoms. , While trees, pollution removal equated to ... percent, the impacts of that improvement are substantial. Researchers ... pollution at nearly $7 billion every year in a ...
(Date:7/25/2014)... the colonial era, 100,000s of people lived on the ... manipulated fire to control the availability of plants they ... continue to use fire to maintain desired habitat and ... U.S. Forest Service,s Pacific Southwest Station, will lead a ... Wildfire Refuge during the Ecological Society of America,s 99th ...
(Date:7/25/2014)... Terra satellite show the different areas that have been affected ... The burn scars show up as reddish-brown splotches of color ... the remote parts of Eastern Russia in the Sakha Republic. ... instrument, it is still possible to see the smoke rising ... below show the devastating number of fires that have plagued ...
Breaking Biology News(10 mins):First national study finds trees saving lives, reducing respiratory problems 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... ON, July 19, 2013 Kidney patients who take calcium ... 22 per cent higher risk of death than those who ... by Women,s College Hospital,s Dr. Sophie Jamal. The study, ... the long-time practice of prescribing calcium to lower phosphate levels ...
... This news release is available in German . ... of text, the brain sends commands to arms and fingers to tap ... transfer this information as electrical pulses that trigger muscles to move. The ... along the spinal cord. For a long time, scientists assumed that ...
... media has expanded to reach an unlikely new target: ... Technology (NIST) have created networks of molecular data similar ... search would allow Facebook users to find all their ... NIST-designed networks could help scientists rapidly sift through enormous ...
Cached Biology News:Calcium linked to increased risk of heart disease and death in patients with kidney disease 2Haste and waste on neuronal pathways 2Haste and waste on neuronal pathways 3Haste and waste on neuronal pathways 4Facebook for molecules 2Facebook for molecules 3
capacity 250 mL...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z35,347-7) ...
Certified by the Biological Stain Commission. For staining fresh peripheral blood smears and blood parasites....
... Aminopropylsilane is perhaps the ... chemistry for microarray experiments. ... for Microarrays provide a ... for printing PCR products ...
Biology Products: